DBV Technologies (NASDAQ:DBVT) Stock Price Up 8.4% – Time to Buy?

DBV Technologies S.A. (NASDAQ:DBVT) shares traded up 8.4% during trading on Monday . The company traded as high as $14.49 and last traded at $14.61. Approximately 374,754 shares changed hands during trading, an increase of 22% from the average daily volume of 307,907 shares. The stock had previously closed at $13.48.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Citizens Jmp increased their price objective on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 30th. Weiss Ratings lowered DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 17th. Wall Street Zen cut DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. Guggenheim reiterated a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a research report on Monday, May 4th. Finally, HC Wainwright reissued a “buy” rating on shares of DBV Technologies in a report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $48.50.

DBV Technologies Stock Up 7.1%

The firm’s 50-day moving average is $15.58 and its 200-day moving average is $19.00. The company has a market capitalization of $854.90 million, a PE ratio of -4.16 and a beta of -0.93.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Thursday, July 16th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.48). DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%.The business had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $0.90 million. As a group, equities research analysts predict that DBV Technologies S.A. will post -2.05 EPS for the current year.

Institutional Investors Weigh In On DBV Technologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC bought a new stake in DBV Technologies in the 1st quarter worth $20,146,000. Vivo Capital LLC raised its stake in shares of DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after acquiring an additional 205,943 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in shares of DBV Technologies during the first quarter worth about $21,159,000. Royal Bank of Canada boosted its holdings in shares of DBV Technologies by 167.1% during the first quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock worth $98,000 after purchasing an additional 2,928 shares during the period. Finally, Elmind Capital LP bought a new stake in shares of DBV Technologies in the first quarter worth about $5,536,000. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.